[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-pain":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,53,76,110,134],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100616063",false,"NCT07300735","Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers","A Comparative Study of Diosmin-Hesperidin and Loratadine for the Prevention of G-CSF Induced Bone Pain in Patients With Hematological Malignancies","Inclusion Criteria:\n\n* Adults 18 to 65 years old\n* Receiving a G-CSF for one of the following indications:\n\nTreatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention following autologous hematopoietic cell transplant\n\n* Patients with or without bone pain associated with G-CSF administration.\n* Willingness to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with solid tumors.\n* Pregnant or breastfeeding women.\n* Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.\n* Patients with pre-existing bone disorders or receiving bone modifying agents\n* Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants.\n* Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim\n* Patients who are unable to understand or provide informed consent","ALL","18 Years","65 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain.\n\nThe study is comparing two oral medications for their effectiveness as a preventive treatment:\n\n* Diosmin-Hesperidin (a flavonoid supplement).\n* Loratadine (a common anti-allergy medication).\n\nThe core question the study is trying to answer is:\n\n* Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine?\n* Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?",[26,27,28],"Hematologic Malignancy","Neutropenia","Bone Pain",[30,31,32,33,34,35,36,37,38,39],"Loratadine","Diosmin","Filgrastim","Granulocyte Colony Stimulating Factor","G-CSF Induced Bone Pain","Hesperidin","Flavonoid","Antihistamine","Prophylaxis","Randomized Controlled Trial","RECRUITING","2026-06-23",{"date":43,"type":44},"2026-06-24","ACTUAL",{"date":46,"type":44},"2025-03-01",{"date":48,"type":20},"2027-07",{"name":50,"class":51},"Alexandria University","OTHER",1,{"id":54,"slug":4,"hasResults":10,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100351619","NCT03858205","Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma","Phase II Multi-Institutional Study of Low-Dose (2Gy) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma","Inclusion Criteria:\n\n* Histologic diagnosis of multiple myeloma\n* Painful bone metastasis (index lesion) that has a radiographic correlate\n* Patient may have had any number of prior chemotherapy\u002Fimmunotherapy regimens (changes to systemic therapy or use of bisphosphonates for 4 weeks before and after RT are allowed, but recording of these changes must be made so it can be accounted for)\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Brief Pain Inventory (BPI) score \\>= 2\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Patients will be ineligible if the index lesion has received prior radiation therapy or prior palliative surgery. Patients may have received prior palliative or primary radiotherapy or surgery to other parts of the body, as long as the index lesion was not in the prior radiation fields and has not received prior palliative surgery\n* Patients will also be ineligible if there is pathologic fracture or impending fracture at the site of the index lesion or planned surgical fixation of the bone at the index lesion\n* Patients with clinical or radiographic evidence of spinal cord or cauda equina compression\u002Feffacement from the index lesion, and\u002For with index lesions located at the skull base or orbital lesions\n* Patients must not be pregnant",{"count":60,"type":20},100,[23],"This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.",[28,64,65],"Metastatic Malignant Neoplasm in the Bone","Plasma Cell Myeloma","2026-06-03",{"date":68,"type":44},"2026-06-05",{"date":70,"type":44},"2019-03-11",{"date":72,"type":20},"2027-03-11",{"name":74,"class":51},"University of Southern California",9,{"id":77,"slug":4,"hasResults":10,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100608137","NCT07197645","Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain","A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain","SOLACE","Inclusion Criteria:\n\n* Participants have had disease progression while on anti-cancer treatment, and are not eligible for the treatments, or their lesions are not amenable to palliative EBRT.\n* Participants must have a histologically confirmed diagnosis of malignancy at any time prior to their participation in this clinical trial with multiple metastatic bone lesions with at least 1 metastatic painful osteoblastic tumor that causes a minimum pain score of 4 on the NRS11.\n* Participants must have bone cancer in one or more skeletal locations as identified by a 99mTc-diphosphonate bone scan within 60 days of dosing. At least one lesion must be osteoblastic. If described as osteosclerotic, radiology confirmation that the lesion is osteoblastic is required. Adequate organ function, including:\n* Renal function, defined as a measured creatinine clearance (CrCl) ≥30 mL\u002Fmin as per Cockroft Gault or based on radioisotope glomerular filtration rate (GFR).\n* Hematologic function, defined as a platelet count of \\>100,000 cells\u002Fmm3 and an Absolute neutrophil count (ANC) of \\>1000 cells\u002Fmm3.\n* Hemoglobin ≥8 g\u002FdL.\n* Liver function:\n* Total bilirubin ≤1.5 × the upper limit of normal (ULN).\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 × ULN with participants with known liver metastases.\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3 × ULN with participants with Gilbert's Syndrome.\n* Life expectancy of at least 16 weeks from the date of study drug administration (Day 1).\n* Karnofsky performance status \\>60%, assessed during the screening period prior to study drug administration.\n\nExclusion Criteria:\n\n* Participants are pregnant or breastfeeding.\n* Participants who have received maximum tolerable radiation to the spinal cord, have untreated pathologic bone fracture, spinal cord compression, unstable spine, or imminent long bone fracture.\n* Participants with a bone scan pattern showing diffuse, intense skeletal uptake with absent or faint kidney \u002F bladder activity, typically indicating widespread bone metastases or high bone turnover from metabolic or hematologic diseases (Superscan) pattern on Technetium 99-m bone scan scintigraphy - defined as diffusely increased skeletal uptake with absent or markedly reduced renal and soft tissue visualization - are excluded from the study.\n* Participants with impending or suspected or at high risk for spinal cord compression.\n* Participants with neurogenic pain or significant pain associated with soft tissue lesions or other pain that, in the opinion of the Investigator, might interfere with the assessment of pain relief for bone tumors.\n* Participants who require surgery over their trial period that would require pain medication or analgesia.\n* Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product.\n* History of unstable angina (defined as angina at rest) or new-onset angina diagnosed within the 3 months prior to screening.\n* History of myocardial infarction within 3 months prior to screening, as determined by medical history \u002F Baseline ECG.\n* Uncontrolled cardiac arrhythmias (≥Grade 3 CTCAE version 5.0) or any history of ≥Grade 3 arrhythmia.\n* Congestive heart failure ≥New York Heart Association Class 2.\n* Clinically significant abnormalities on ECG at screening including corrected QT interval (Fridericia's formula) \\>450 msec for males or 470 msec for females at screening.\n* Inability to complete the needed investigational and standard imaging examinations due to any reason (eg, severe claustrophobia, inability to lie still for the entire imaging time).\n* Presence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study Investigator, would make the participant inappropriate for entry into the study.\n* Participants with active infections (human immunodeficiency virus, human papillomavirus. Hepatitis A, Hepatitis B, and Hepatitis C).",{"count":84,"type":20},33,[86],"PHASE1","This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.",[28,89,90],"Metastatic Bone Tumor","Bone Metastases in Subjects With Advanced Cancer",[92,93,94,95,96,97,98],"samarium","radioligand","radioisotope","metastatic bone pain palliation","Samarium-153","DOTMP","bone-seeking radiopharmaceutical","2026-05-12",{"date":101,"type":44},"2026-05-14",{"date":103,"type":44},"2025-10-21",{"date":105,"type":20},"2027-07-05",{"name":107,"class":108},"Telix Pharmaceuticals (Innovations) Pty Limited","INDUSTRY",6,{"id":111,"slug":4,"hasResults":10,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":130,"leadSponsor":132,"locationsCount":52},"100599871","NCT07090122","Radiofrequency Ablation\u002FBone Augmentation + Radiotherapy vs Radiotherapy Alone","Inclusion Criteria:\n\n* Histologically confirmed metastatic T5-L5 disease of the spine (with up to two levels) as detected by any imaging study.\n* Have either associated bone pain or cross-sectional imaging characteristics that are predictors of SRE.\n* Age 18 years of age or older at the time of consent.\n* Have adequate organ function confirmed by the following laboratory values obtained within 14 days prior to study enrollment defined as:\n\n  1. absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL\n  2. platelets ≥ 50 × 109\u002FL\n  3. hemoglobin ≥ 10 g\u002FdL, independent of transfusion ≤14 days of screening\n  4. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); if liver metastases, then ≤ 5 × ULN\n  5. total bilirubin ≤ 1.5 × ULN; \\\u003C 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome\n  6. serum albumin ≥ 30 g\u002FL (3.0 g\u002FdL)\n  7. serum creatinine ≤ 1.5 x ULN; OR estimated glomerular filtration rate (GFR) ≥ 45 mL\u002Fmin using the Cockcroft Gault formula\n* Persons of childbearing potential (POCB) or with partners of childbearing potential must be willing to use contraception during study treatment and 6 months after study treatment.\n* Persons are considered to be of childbearing potential unless one or the following applies:\n\n  1. Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause\n  2. Considered permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and\u002For bilateral oophorectomy\n* Voluntary written consent prior to the performance of any research related activity\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Clinical or radiologic evidence of epidural spinal cord compression or radicular pain.\n* Prior radiation therapy to the target lesion.\n* Candidates for spine stabilization surgery.\n* The target lesion(s) is deemed ineligible for RFA\u002FBA (e.g. unstable existing fractures\u002Fimpending fractures, involvement of the posterior elements, retropulsion, spinal canal narrowing, neuroforaminal narrowing, uncontrolled bleeding diathesis, active infection anywhere in the body, or purely blastic tumor). Note: Mixed lytic\u002Fblastic tumors are eligible.\n* The target lesion(s) size or location is beyond RFAs ability to safely perform, at the physician's discretion",{"count":116,"type":20},36,[23],"This is a single-center, randomized controlled pilot study of radiofrequency ablation and bone augmentation (RFA\u002FBA) plus radiotherapy (RT) vs. RT alone in patients with metastatic T5-L5 disease of the spine. Patients will be randomized 2:1 to receive either one treatment of RFA\u002FBA plus RT or RT to evaluate the occurrence of skeletal-related events. Skeletal-related events (SREs) are defined as new clinical or radiologic evidence of pathologic fracture, spinal cord or nerve root compression, pain or instability, and\u002For necessity for additional local intervention (i.e. surgery, repeat RFA\u002FBA or RT) due to persistent or progressive symptoms. Post-treatment follow-up for SREs are assessed at 1, 3, 6, 12, and 24 months.",[120,28],"Spine Metastases",[122,123,124,125],"Radiofrequency ablation (RFA)","Bone augmentation (BA)","Radiotherapy (RT)","Metastatic disease of the spine","2025-12-01",{"date":128,"type":44},"2025-12-03",{"date":126,"type":44},{"date":131,"type":20},"2028-06-13",{"name":133,"class":51},"University of Minnesota",{"id":135,"slug":4,"hasResults":10,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":10,"sex":140,"minAge":16,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":152,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":52},"100503893","NCT05841186","Correlation of Timing of Pegfilgrastim Administration and PIBP.","Correlation of Timing of Pegfilgrastim Administration and PIBP(Pegfilgrastim-induced Bone Pain)","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years and less than or equal to 70 years.\n2. Pathologically or histologically confirmed diagnosis of primary breast cancer.\n3. Able to receive the chemotherapy regimen as scheduled.\n4. Able to understand Chinese and fill out the study-related questionnaires independently.\n5. Given written informed consent.\n6. There is no need to use prescription or over-the-counter drugs regularly because of pre-existing chronic pain.\n\nExclusion Criteria:\n\n1. Suffering from bone pain due to other diseases currently.\n2. Allergy or contraindication to chemotherapeutic agents or pegfilgrastim.\n3. Previous use of pegfilgrastim.\n4. Previous received chemotherapy.\n5. Pregnancy or breastfeeding.\n6. Concurrently accompanied by other primary malignant tumors.","FEMALE","70 Years",{"count":143,"type":20},156,[23],"According to the National Comprehensive Cancer Network (NCCN) guidelines, patients receiving high-risk or moderate-risk febrile neutropenia (FN) chemotherapy with at least one risk factor should receive prophylactic granulocyte colony-stimulating factors (G-CSFs). However, pegfilgrastim-induced bone pain (PIBP) remains a common and significant clinical issue without a satisfactory solution. Studies have reported that the incidence rate of PIBP is 71.3%, with severe bone pain occurring in 27.0% of cases. Currently, the available data on PIBP treatment are limited to case reports, reviews, and small randomized controlled trials.\n\nThe NCCN guidelines recommend preventive oral non-steroidal anti-inflammatory drugs or antihistamines as the treatment for PIBP. However, even with these preventive measures, the incidence rate of PIBP remains high at 61.1%, with severe bone pain occurring in 19.2% of cases. Severe bone pain can significantly impact the patient's health-related quality of life (HRQol), leading to potential refusal of pegfilgrastim administration and subsequent dose reduction in effective chemotherapy. Ultimately, this may have negative implications for tumor cure rates and patient survival.\n\nBased on previous literature, it appears that delaying the administration of pegfilgrastim may be associated with a lower incidence of PIBP. Therefore, our study aims to investigate the correlation between the timing of pegfilgrastim administration and the occurrence of PIBP.",[147,28,148,149,150,151],"Pegfilgrastim","Chemotherapy","Breast Cancer","Patient-reported Outcomes","Quality of Life",[153,154,155,156,149,157],"pegfilgrastim","bone pain","patient-reported outcomes","chemotherapy","health related-quality of life","2024-09-09",{"date":160,"type":44},"2024-09-19",{"date":162,"type":44},"2023-05-04",{"date":164,"type":20},"2025-05-31",{"name":166,"class":51},"Guangdong Provincial People's Hospital",""]